Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6Brain Neoplasms 3Neoplasms 2Lung Neoplasms 2Thrombophilia 1Stomatitis 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Periodontitis 1Patient Satisfaction 1Neoplasms, Plasma Cell 1Motor Activity 1Liver Neoplasms 1Liver Diseases 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Febrile Neutropenia 1EGFR-Mutant Lung Cancer 1Deglutition Disorders 1Communication Disorders 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Diseases 1Blood Coagulation Disorders 1Advanced Breast Cancer 1

Interventions

Fulvestrant 18Letrozole 10Anastrozole 8Capecitabine 5palbociclib 4olaparib 4Paclitaxel 4Goserelin 4Docetaxel 4pyrotinib 3exemestane 3Vinorelbine 3Injections 3Aromatase Inhibitors 3trastuzumab deruxtecan 2toripalimab 2sacituzumab govitecan 2ribociclib 2eribulin 2elacestrant 2dalpiciclib 2abemaciclib 2Trastuzumab 2Gonadotropin-Releasing Hormone 2FCN-437c 2Everolimus 2Dasatinib 2Alpelisib 2Albumin-Bound Paclitaxel 2AZD9833 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Cancer × Lead × Clear all
NCT05085002 2026-05-14

A Study of Lerociclib in Participants With Advanced Breast Cancer

EQRx International, Inc.

Phase 2 Terminated
100 enrolled 14 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡